Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dollar General Corp. (DG) vs Johnson & Johnson (JNJ) Price & Performance

Dollar General Corp.Trade
Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

Dollar General Corp. vs Johnson & Johnson — how do they compare? Dollar General Corp. trades at $126.5 (market cap $27.42B), while Johnson & Johnson trades at $261.05 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 22.5× Dollar General Corp.'s market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Johnson & Johnson for 129 Days on average.

DGJNJ
Market Cap
$27.42B$618.09B
Volume
2,291,5176,050,983
Sector
Consumer StaplesHealth
52-Week High
$156.26$278.43
52-Week Low
$95.94$186.00
Typical Hold Time
59 Days129 Days
Enterprise Value
$41.60B$646.37B
Dividend Yield
1.9%2.09%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dollar General Corp.

Dollar General (DG) trades at $126.16, up 3.27% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows solid fundamentals with a P/E of 16.14 and ROE of 19.69%, supported by positive cash flow trends and a growing revenue base. Recent news highlights strategic initiatives like tariff refunds, delivery expansion with Instacart, and the DG Media Network, enhancing its value-retail positioning.

The outlook for DG is positive, driven by earnings momentum and analyst consensus pointing to a $137.27 price target. Key opportunities include margin expansion from cost initiatives and digital growth, while risks involve competitive pressures and consumer spending sensitivity. The stock presents a compelling case for value investors seeking steady growth in the discount retail sector.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.

JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DG

No sentiment data available yet.

JNJ
96% Buy4% Sell
Avg holding period · 129 Days

Top news

Latest headlines on both assets

About Dollar General Corp.

A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.

Read more on DG →

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ →